SenoRx

Irvine, United States Founded: 1998 • Age: 28 yrs Acquired By CR Bard
Minimally Invasive devices for breast cancer treatment diagnosis
Annual revenue - Latest available
Total funding - Funding intelligence
Employees - Tracked headcount
Investors 1 Known backers
Products - Services tracked
Competitors 9 Brand Intelligence

About SenoRx

SenoRx is a company based in Irvine (United States) founded in 1998 was acquired by CR Bard in May 2010. SenoRx operates in a competitive market with competitors including Elucent Medical, Cianna Medical, OncoStem, Curasight and PreludeDx, among others.

  • Headquarter Irvine, United States
  • Stage Public
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Senorx Llc
Operational Areas
Healthcare → Health Technology & Digital Health
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Latest Funding Round
  • Investors
  • Employee Count
    Employee Count
  • Acquired by
    CR Bard

    (May 05, 2010)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of SenoRx

Investors in SenoRx

SenoRx has secured backing from 1 investor. Prominent investors backing the company include CR Bard.

All
Investor Description Founded Year Domain Location
Products for vascular, urology, oncology, and surgical specialties
Founded Year Domain Location

Investments & Acquisitions by SenoRx

Investments

Financial Statements - SenoRx

Senorx Comparisons

+
Add Comparison
Available on Premium

Competitors of SenoRx

SenoRx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Elucent Medical, Cianna Medical, OncoStem, Curasight and PreludeDx, among others.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Develops smart surgical guidance systems with in-body spatial intelligence for accuracy.
domain founded_year HQ Location
Breast brachytherapy devices and surgical guidance systems are developed.
domain founded_year HQ Location
Prognostic tests for cancer detection and recurrence risk are developed.
domain founded_year HQ Location
uPAR-based PET ligands for breast cancer imaging are developed.
domain founded_year HQ Location
Risk assessment tests for early-stage breast cancer are provided.
domain founded_year HQ Location
Telomere tests for aging detection and cellular senescence are provided.

Latest news on Senorx

Frequently Asked Questions about SenoRx

SenoRx was founded in 1998.

SenoRx is headquartered in Irvine, United States. It is registered at Irvine, California, United States.

SenoRx(previously known as BiopSolation Medical) designs, develops, manufactures and markets minimally invasive devices for the diagnosis and treatment of breast cancer. SenoRx (NASDAQ: SENO) completed its initial public offering of common stock in March 2007. Its products include the EnCor vacuum-assisted breast biopsy system, the Contura Multi-Lumen Balloon (MLB) applicator for delivering radiation to the tissue surrounding the lumpectomy cavity following surgery for breast cancer, and SenoSonix, which combines ultrasound and vacuum-assisted biopsy in one system. It offers vacuum-assisted breast biopsy systems, breast tissue markers, breast localization wires, core needle biopsy products, sentinel node detection products, and disposable bone and aspiration biopsy needles. The companys products are used with ultrasound, stereotactic, and MRI. SenoRx sells several of its products through distribution partners in more than 30 countries outside the U.S. and Canada. The companys line of breast care products includes biopsy disposables, biopsy capital equipment, diagnostic adjunct products and therapeutic disposables. SenoRx was acquired by CR Bard in 2010 for 213M.

SenoRx's top competitors include PreludeDx, OncoStem and Curasight.

SenoRx has 1 investor. Key investors include CR Bard.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available